Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 12/18/15 -- announced today that it has updated coverage on Soligenix, Inc. ("The Company" or "SNGX") (OTCBB: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, and maintains its twelve-month price target of $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "On December 16, 2015, Soligenix reported positive preliminary data from the Phase 2 trial of their clinical candidate SGX942 for the treatment of oral mucositis associated with head & neck cancers. SGX942 is a novel synthetic peptide that modulates anti-inflammatory and anti-infective activity of the innate immune response (an 'Innate Defense Regulator, IDR') On the Company hosted investor conference call held December 16th, which was organized to discuss the data from the SGX942 Phase 2 trial, I asked the CEO of Soligenix, Chris Schaber, what he believed the estimated net present value ("NPV") of SGX942 was given the data. As a reminder, the market cap of Soligenix at the time of our publication is approximately $25M, 4x less than $100M which equates to a share price of approximately $4, again, just for SGX942." Mr. Silver concludes, "Randal J. Kirk, the CEO of Intrexon which has approximately a $3.8B market cap, has a beneficial ownership position of approximately 23% of Soligenix. In addition, Paolo Cavazza's beneficial ownership position on his own behalf and on behalf of Sigma-Tau is approximately 12% of Soligenix."
To download a FREE copy of the research report, please visit and click the "download research" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.
Please follow us on & at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website or click .
Contact:
Vista Partners
877.215.4813
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.12.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 440653
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00"
steht unter der journalistisch-redaktionellen Verantwortung von
Vista Partners (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
